- Home
- MNOV vs HUCK Comparison
MNOV vs HUCK Comparison
Compare MNOV & HUCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | HUCK |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 159.5M |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MNOV | HUCK |
|---|---|---|
| Price | $1.42 | $3.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $8.25 | $4.17 |
| AVG Volume (30 Days) | ★ 786.3K | 759.8K |
| Earning Date | 11-11-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.92 |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $318,857,000.00 |
| Revenue This Year | $78.20 | N/A |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | 0.57 |
| 52 Week Low | $1.17 | $2.98 |
| 52 Week High | $3.90 | $3.55 |
Technical Indicators
Market Signals| Indicator | MNOV | HUCK |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 34.32 |
| Support Level | $1.29 | $3.00 |
| Resistance Level | $1.48 | $3.45 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 1.55 | 29.47 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.